Gilead’s HCV Authorized Generics Effort Will Draw Market Share From AbbVie
Executive Summary
By marketing its own authorized generic versions of blockbuster HCV combos Epclusa and Harvoni, Gilead may eat into AbbVie’s large market share edge in US government-insured patients.
You may also be interested in...
Louisiana ‘Netflix’ Model For Hepatitis C Drugs Caps Spending At $35m Per Year
Purchasing contract for state Medicaid and Corrections programs would last up to five years and aim to treat more than 10,000 patients in first year.
AbbVie Hit Harder By EU Humira Biosimilars Than Projected
The Q3 earnings call was the first time AbbVie management had to face the masses since the mid-October launch of adalimumab biosimilars across Europe. CEO Gonzalez predicted ex-US Humira revenue erosion of 26%-27% this year, higher than previous estimates.
AbbVie Hit Harder By EU Humira Biosimilars Than Projected
The Q3 earnings call was the first time AbbVie management had to face the masses since the mid-October launch of adalimumab biosimilars across Europe. CEO Gonzalez predicted ex-US Humira revenue erosion of 26%-27% this year, higher than previous estimates.